NCT03713086

A Study to Assess the Safety, Reactogenicity and Immune Response of CureVac's Candidate Rabies mRNA Vaccine in Healthy Adults

A Non-Randomized, Open Label, Controlled, Dose-Escalation, Phase I Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of One or Two Administrations of Candidate Rabies mRNA Vaccine CV7202 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 53 (actual)
• Sponsor: CureVac · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this clinical study is to assess the safety, and reactogenicity of CV7202 mRNA-rabies vaccine in healthy adults. Immunogenicity is also assessed.

Conditions

• Rabies

Interventions

Type	Name	Description
BIOLOGICAL	Rabipur®	3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
BIOLOGICAL	Rabies mRNA vaccine CV7202	CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
BIOLOGICAL	Rabies mRNA vaccine CV7202	CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm
BIOLOGICAL	Rabies mRNA vaccine CV7202	CV7202 administered IM at Days 1 and 29 in the deltoid region of the arm

Timeline

• Start date: 2018-10-12
• Primary completion: 2021-11-23
• Completion: 2021-11-23
• First posted: 2018-10-19
• Last updated: 2024-12-19
• Results posted: 2024-12-19

Locations

2 sites across 2 countries: Belgium, Germany